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A B S T R A C T
COVID-19 vaccines are by no means a silver bullet. With more COVID-19 vaccines expecting approval in the
coming months, it is necessary to note that vaccine availability does not equate to vaccine accessibility, nor
vaccine efficacy. Some research suggests that approximately 9 out of 10 individuals living in lower-income
countries will not have access to COVID-19 vaccines until 2023 or later. For higher-income countries, such as
the United States, the prevalence of vaccine hesitancy may further compound the situation. These insights
combined, in turn, emphasize the fact that even though COVID-19 vaccines are becoming more available, safety
measures (e.g., face masks, personal hygiene, and social distancing) are still of pivotal importance in protecting
personal and public health against COVID-19. Furthermore, this paper argues for the continued imperative for
health experts and government officials to communicate and emphasize the importance of COVID-19 safety
measures with the public, to make sure people are protected against COVID-19 till the pandemic ceases to pose a
threat to personal or public health.
The coronavirus 2019 (COVID-19) vaccines are becoming more
available, starting from the first approval and the distribution of Pfizer-
BioNTech vaccines in the United Kingdom’s (U.K.) on December 8th,
2020 (World Health Organization, 2020). As of January 28th, 2021, in
addition to Pfizer-BioNTech, vaccines developed by nine other com-
panies, ranging fromOxford-AstraZeneca, Sinopharm, to Gamaleya, have
all been utilized for mass inoculation across the world, while 20 vaccines
are currently at the final stage of the clinical trial (World Health Orga-
nization, 2020). Over the coming months, more countries will begin
approving vaccines. No doubt that amid an avalanche of negative news
about the pandemic, reports on COVID-19 vaccines serve as rays of hope.
It is important to note, however, that these vaccines are not yet a silver
bullet; for starters, vaccine availability does not equate to vaccine
accessibility (e.g., vaccine equity issues) (Paltiel et al., 2020). Further-
more, COVID vaccines’ real-world efficacy should also consider factors
ranging from vaccine delivery challenges, distribution hurdles, to po-
tential side effects. Not to mention vaccine hesitancy, a prevalent and
persistent issue many countries face, could further compound the situa-
tion (Su et al., 2020a,b).
Even though scientists have been working on COVID-19 vaccines at
an unprecedented speed, data are still scarce when it comes to questions
such as “Can one spreads COVID-19 after vaccination?”, “How long will
the vaccine protect vaccinated people from the virus?”, and “Will COVID-
19 be eradicated, or develop a transmission pattern that is similar to
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seasonal influenza?” (Centers for Disease Control and Prevention, 2021a;
Kissler et al., 2020). These insights combined suggest that even though
COVID-19 vaccines are becoming more available, the continued
communication and implementation of COVID-19 safety measures (e.g.,
face masks, personal hygiene, and social distancing) are still instrumental
to effective pandemic control and containment. Despite the positive news
about COVID-19 vaccines, health experts and government officials must
continue communicating the unwavering imperative for the public to
adhere to COVID-19 safety measures till the pandemic ceases to pose a
flagrant threat to personal or public health.
1. COVID-19 vaccine availability vs. vaccine accessibility
Thoughmore COVID-19 vaccines will become available in the coming
months, it is important to understand that, due to limitations in vaccine
production, not all people will have the same level of access. The U.K., for
instance, prioritized people who are most vulnerable to COVID-19 in-
fections, such as older adults and frontline workers (e.g., healthcare
professionals), over the rest of the population (Department of Health and
Social Care, 2021). Vaccine distribution policy in the United States
(U.S.), on the other hand, will be heavily influenced by how each of its 50
states determines to roll out the vaccines and it could be difficult to
predict how the trajectory of mass inoculation of different states (Centers
for Disease Control and Prevention, 2020b). In New Jersey, for instance,
where smoking is classified as a medical condition, nearly two million
smokers will be eligible to get a vaccine in the state, regardless of
whether they are older adults (Arco, 2021). In contrast, Florida’s decision
to include both residents and nonresidents has effectively fueled a
“vaccine tourism,” where foreigners who are 65 years older and are
sharing available vaccine doses with residents (Campo-Flores and
Cordoba, 2021). While writing this paper, Florida has changed its poli-
cy—people who receive COVID-19 vaccines need to provide a proof of
residence (Sarasota County Government, 2021). In other words, now
“vaccine tourism” in Florida will only apply to those who could afford to
maintain a permanent or seasonal residensy status—vaccine inequality is
still present, but only for the super rich.
Accessing COVID-19 vaccines will be substantially more difficult for
people living in lower-income countries. Even with the help of COVAX, a
vaccine alliance organized by the World Health Organization that hopes
to bridge COVID-19 vaccine equity, approximately 9 out of 10 people
living in 70 poor income countries will not be able to have access to
COVID-19 vaccines till 2023 or later (Duke Global Health Innovation
Center, 2021). One key contributor to this inequality centers on vaccine
nationalism— rich countries have been disproportionately hoarding
doses to exacerbate the COVID-19 vaccine shortage further. In early
December 2020, Canada, for instance, has already ordered a stockpile of
COVID-19 vaccines that are enough to inoculate each Canadian five times
(601%, by share of the population able to vaccinated with), followed by
the U.S. (442%), the U.K. (419%), Australia (267%), and the European
Union (246%) (Doucleff, 2020).
2. COVID-19 vaccine availability vs. vaccine efficacy
The efficacy of COVID-19 vaccines in protecting the public from po-
tential infections and deaths is also highly dependent on key contextual
factors, ranging from vaccine potency, implementation, and vaccine
hesitancy (Centers for Disease Control and Prevention, 2020b; Su et al.,
2020a,b). Vaccine approval is followed by mass production, the process
of which, in light of the competition for critical resources and logistical
challenges, is highly dependent on an array of factors, ranging from the
accessibility of glass vials, syringes, and needles, to advanced cold chain
systems (United Nations International Children’s Emergency Fund,
2020). Vaccines are delicate health products that need special attention
in their delivery and distribution; any hiccups in COVID-19 vaccines’
supply chain have the potential to harm COVID-19 vaccine efficacy
(Paris, 2020). Some vaccines, such as the first clinically-authorized and
fully-tested coronavirus vaccine, Pfizer-BioNTech vaccine, need to be
stored in extremely cold environments (i.e., 70 C  10 C) throughout
its delivery to end-users (Pfizer, 2020). In other words, the efficacy of
some COVID-19 vaccines could become vitally compromised if the
temperature is not maintained throughout the delivery process (Pfizer,
2020).
There is also a last-mile issue. Individuals will receive their COVID-19
vaccine in health facilities that may have varying degrees of competency
in terms of staff training, equipment maintenance, and safety vigilance,
and in turn, success in vaccine administration (Centers for Disease Con-
trol and Prevention, 2020b; National Health Service, 2020). The fact that
many health systems, especially their healthcare professionals, have been
overstretched and overstressed, may further compound the situation
(Weber, 2020). In addition to mental health issues faced by the general
public (Su et al., 2020a,b), emerging evidence shows that frontline
workers also have to cope with substantial trauma or stress-related dis-
orders, ranging from anxiety, depression, to fear of stigma and isolation
(Cabarkapa et al., 2020). This could lead to substantial human and eco-
nomic consequences. In the U.S., for instance, healthcare workers in the
state of West Virginia have accidentally “inoculated” 42 people with an
experimental monoclonal antibody treatment, as opposed to COVID-19
vaccines (Wolfe, 2020). Compared to issues such as unknown
short-term and long-term side effects, perhaps the least worrisome fact in
this incident is that the antibody treatment is only approved to be given
in an intravenous infusion, rather than a shot in the arm. Fortunately, to
date, no substantial side effects have been reported in these 42 people.
Compared with their more affluent counterparts, poorer countries
might have to shoulder additional challenges in vaccine administration,
as these countries face added pressures such as the lack of necessary
infrastructure needed for a successful COVID-19 vaccine distribution
(Nkengasong et al., 2020). What also needs consideration is how vaccine
updates are communicated to the public; because there are currently
multiple vaccines, each with different costs, efficacy rates, and clinical
trial reports and, as such, there will likely be variations in the process of
implementation. Additionally, challenges in access to vaccines, lower
socioeconomic areas, or countries with less advanced medical and health
infrastructure, for example, means that a direct comparison of method-
ological processes and evaluations will also differ. Even assuming that
vaccine dissemination goes as planned, the society at large has still yet to
figure out fundamental questions such as: (1) Whether people can spread
COVID-19 after vaccination, (2) How long will COVID-19 vaccines pro-
tect vaccinated people from the virus, (3) What will be the impact of virus
mutations, such as the B.1.1.7 variant, on COVID-19 vaccine efficacy, and
(4) Will COVID-19 be eradicated, or progress into a transmission pattern
that is similar to seasonal influenza (Centers for Disease Control and
Prevention, 2021a; Kissler et al., 2020)?—Questions that are crucial to
gain an in-depth, comprehensive, and evidence-based understanding of
COVID-19 vaccines’ abilities to control and contain the pandemic.
It is also important to note that COVID-19 vaccine efficacy will be
substantially impacted by the scale of the virus’ infection in a society
(Paltiel et al., 2020). In the U.S., research suggests that for countries with
a high level of COVID-19 infection, even with a vaccine distribution of
95% efficacy and without substantial complications, after six months of
vaccination, roughly 10 million infections and 160,000 deaths could still
be added to the U.S.’s overall COVID-19 patient pool (Paltiel et al., 2020).
Data on COVID-19 vaccines’ potential drug interactions are even more
scarce, partially because mass inoculation of COVID-19 is either just
started or still pending official approval. What is clear, though, is that
side effects of COVID-19 are inevitable—available evidence shows that at
least four volunteers developed Bell’s Palsy or partial facial paralysis
during the Pfizer-BioNTech’s vaccine trial period alone (Centers for
Disease Control and Prevention, 2020b). As of early January 2021, rates
of anaphylaxis or allergic reactions associated with Pfizer-BioNTech
vaccines are 11.1 per one million, substantially higher than those of
seasonal influenza vaccines, which is 1 per one million (CDC COVID-19
Response Team & U.S. Food and Drug Administration, 2021). In the
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same month, a Florida doctor has developed a rare severe blood disorder
and died shortly after receiving the Pfizer-BioNTech vaccine (Grady and
Mazzei, 2021).
Vaccine hesitancy may further compound the situation. A recent na-
tionally representative poll jointly conducted by the Associated Press and
the University of Chicago indicates that only 47% of Americans have the
intention to update COVID-19 vaccines (AP-NORC, 2020). Among 19
respiratory therapists who intubate severely ill COVID-19 patients at
Long Island Jewish Hospital in New York City, only 3 of them agreed to
be vaccinated (Robbins et al., 2021), even though they are at pronounced
risk of contracting the virus. As reports on COVID-19’s side effects begin
to merge, fact-based conversations, as well as infodemics, may further
cause vaccine hesitancy to rise (Su et al., 2020a,b). These factors, taken
together (see Fig. 1), underscore the fact that COVID-19 vaccines are not
yet a silver bullet in controlling the pandemic, and more importantly, the
imperative for the public’s continued adherence to COVID-19 safety
measures, such as masking, maintaining personal hygiene, and social
distancing, even though uplifting news on COVID-19 vaccines is mush-
rooming. In other words, in addition to sharing positive news on
COVID-19 vaccines with the public, health experts and government of-
ficials also need to continually remind people of the importance of
holding fast to effective COVID-19 prevention strategies till the pandemic
ceases to be a threat to personal or public health.
3. The need for continued communication about COVID-19
safety measures
The need for COVID-19 safety measures is particularly pronounced
during the distribution planning months when news on COVID-19 vac-
cine approval could be mediated by biased perceptions of data and
inaccurate reports (Bastian, 2020). As inaccurate or misleading
communication about the vaccines could lead to oversized, or even ir-
rational exuberance, that could cause the public to miscalculate their
susceptibility to COVID-19. These months, between December 2020 to
March 2021, are also when most of the northern hemisphere experiences
the first COVID-19 winter—a time when efforts of treating COVID-19 can
be hindered by a higher prevalence of seasonal influenza, longer time
spent indoors, and more holiday-season gatherings, compared to warmer
seasons (Gorman and Trotta, 2020).
Vaccines are not the panacea for the COVID-19 pandemic control and
containment. To continue to protect personal and public health, health
experts and government officials have a responsibility to help people
understand and remember the imperative to continue their preventive
health measures: wearing a mask, washing hands properly and
frequently, and social distancing, especially when the public’s height-
ened exposure to positive news on COVID-19 vaccines might lower their
guard against COVID-19. In light of phenomena such as the “COVID-19
fatigue” or “mask fatigue”, along with the tsunami of fact-based
Fig. 1. Issues that could compromise COVID-19 vaccines’ capabilities to help control and contain the pandemic.
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information and fake news amid the pandemic, to persuade people to
adhere to safety measures amid positive news about COVID-19 vaccines,
healthcare and government officials should not only inform the public
about the need to stick to safety rules or regulations, but also persuade
them to conform to these COVID-19 measures (Su et al., 2020a). Prin-
ciples of persuasive communication rooted in behavioral sciences indi-
cate that the efficacy of a health message is not only determined by “what
to say,” but also “how to say it” (Kahneman and Tversky, 1979). In other
words, though the content is the same, whether a message is framed as “a
staggering of 25.6million Americans have been infected with COVID-19
as of January 28th, 2021” or “a reassuring majority of 302.6 million
Americans have steered clear of COVID-19 as of January 28th, 2021”will
affect how the public evaluate the pandemic and react to COVID-19
safety measures.
Many health communication and behavioral psychology approaches
can be applied to the COVID-19 context. Reinforcing compliance be-
haviors whilst simultaneously informing communities regarding the
dangers of complacency could be a practical campaign concept. For
instance, a recent study finds that when campaign messages are tailored
to trigger thoughts of infecting a large number of people or vulnerable
individuals, people will more likely adhere to social distancing rules
(Lunn et al., 2020). Compared to other types of health care service
messages, when social media posts are framed in a disease prevention
narrative, messages are more likely to foster social engagement (e.g.,
comments and information exchange) (Ngai et al., 2020).
In light of COVID-19 infodemics, health expert promotions of COVID-
19 safety measures have seen varying levels of implementation.
Considering the potential cases of COVID-19 infection and death, nar-
ratives surrounding the need to “wear face masks when you take public
transportation” or “not take public transportation when you are unwell”,
could further drive the much-needed community-driven health response.
In other words, to help societies avoid transmission vectors and start
imagining the “new normal”, continued communication about the need
for face masks, personal hygiene, and social distancing is of instrumental
importance. While it is expected for some compliance to become a
concern throughout this time of year, reigniting past campaigns and
encouraging communities to continue doing their part is a must. In
China, for instance, the Lunar New Year, a holiday that starts on February
12th in 2021 and traditionally celebrated in the unit of the family, can
incentivize the largest human migration on earth— in a normal year,
around three billion trips occur during the Spring Festival (Tan, 2021).
For some Chinese people, especially migrant workers, the Spring Festival
is often the only time they get to see their family members and pay proper
respects to the dead (Tan, 2021). How to effectively and equitably
persuade people to refrain from traveling amid the Chinese New Year are
two Herculean tasks health experts and government officials in China
must conquer in order to: (1) protect personal and public health from
avoidable COVID-19 infections and deaths, (2) safeguard Chinese peo-
ple’s need for love and belonging amid the most important holiday sea-
son of the year, and (3) make sure people can travel safely and freely to
celebrate the Chinese New Year in 2021 and beyond.
4. Special communication efforts for international travel
Unlike other social contexts, international travel is unique in that
individuals may be subjected to multiple, and possibly contradicting as
well as capricious, COVID-19 safety mandates. These issues are seen in
chaotic international responses towards the news about COVID-19 mu-
tations, such as B.1.1.7 first identified in the U.K., range from travel bans
of incoming U.K. travelers to widespread cancellation of all international
flights, most of which issued within hours of the U.K. announcement
(Booth and Noack, 2021). Inconsistencies in international travel policies
amid COVID-19 can also be found elsewhere. Different from the rest of
the countries across the world, several nations have begun to require
international travelers to produce a negative COVID-19 test certificate
before crossing their borders (Pitrelli, 2020). People who travel by air
into the U.S., for instance, would be mandated to present proof of a
negative COVID-19 test starting from January 26th, 2020 (Centers for
Disease Control and Prevention, 2021b). This suggests that, as infection
rates fluctuate, it is even possible for the same country to be reflexive and
issue differing guidelines and safety mandates across time. These con-
flicting COVID-19 health and communication policies and directives
have the potential to compromise travelers’ understanding of the specific
rules and regulations they need to follow, which in turn, could result in
severe personal and public health consequences.
As the struggling tourism and hospitality industries slowly recover,
travelers may have pinned their hopes on returning to the pre-pandemic
normality with a COVID-19 vaccine. Airlines have been responsive to
vaccine updates, especially when the idea of using an immunity passport
to track a traveler’s COVID-19 status has been theorized for some time
(Centers for Disease Control and Prevention, 2020a). Companies, such as
Qantas, recently announced plans to make it compulsory for all future air
passengers to be vaccinated before being allowed to board a flight
(Pitrelli, 2020). Technologies can also help. Companies such as Micro-
soft, Oracle, Salesforce, and Mayo Clinic are working together to develop
technology-based mechanisms that would enable people to electronically
share their immunization records via a COVID-19 health passport app
(Singer, 2020). In theory, such measures can prevent COVID-19 from
spreading. Still, even with the most effective vaccines currently available,
the ideal rates are only 95% effective in protecting people from con-
tracting COVID-19 (Wen and Su, 2020), without factoring in other
compounding variables such as numbers needed to treat. In other words,
infection and transmission are still possible. Inadvertently, international
fights may expose a substantial number of people, living in the destina-
tion or fly-over countries, to the harms of COVID-19 (Wen and Su, 2020).
COVID-19 vaccines are no silver bullet to safeguard international
travel, at least not yet. This is especially true as COVID-19 vaccines, as
highlighted above, will not be available for all travelers simultaneously
for pragmatic and logistical reasons (BBC, 2020). In reality, it is almost
impossible for COVID-19 vaccines to be 100% effective for all de-
mographics (Centers for Disease Control and Prevention, 2020b). What is
possible is that international travelers, whether they received a vaccine
or not, will be required to comply with different countries’ COVID-19
safety measures (e.g., quarantine) that are subject to change across
time. It is difficult to predict how the “travel bubble” experiments
progress, a mechanism that allows international travelers arriving from
low-risk countries (e.g., New Zealand and Australia) to be exempt from
quarantine regardless of vaccination status (Taylor and Remeikis, 2020).
What is clear is that even if these “travel bubbles” are effective, consid-
ering the scale of COVID-19 infections in most countries across the globe
(Johns Hopkins University, 2020), the majority of travelers must still be
vigilant of COVID-19 safety measures while crossing borders.
Taken together, in addition to having a disaster readiness mindset (Su
et al., 2021), these insights further underscore the importance of inter-
national cooperation and collaboration among health experts and gov-
ernment officials across the globe regarding communicating the necessity
of and implementing safety measures, such as masking, personal hygiene,
and social distancing, until COVID-19 ceases to be an active pandemic.
Citizens and international travelers are two markedly different audi-
ences, partially since they may have different levels of familiarity with
the destination or fly-over nations’ COVID-19 safety rules and regula-
tions. Effective communication of COVID-19 safety measures with citi-
zens and international travelers requires health experts and government
officials worldwide to develop tailored communication strategies for a
broad and diverse audience—a daunting, yet necessary task to achieve,
especially in light of the limitations with COVID-19 vaccines accessibility
and efficacy.
The most cost-effective approach might require international health
experts and public officials to collaborate in developing evidence-based
and practical COVID-19 safety and communication plans that factor in
the broader needs and preferences (e.g., preferred communication style
or languages) of all stakeholders. While COVID-19 vaccines are not yet a
Z. Su et al. Brain, Behavior, & Immunity - Health 12 (2021) 100204
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silver bullet, international cooperation and collaboration in communi-
cating the necessary health information the public needs to know for
controlling and containing the pandemic might be. Until the pandemic is
curbed, the world must work in unity to deliver a clear, concise, and
coherent message to the public—masks are a must, personal hygiene can
help clean out the pandemic, and momentary social distancing can bring
the world closer in due time.
List of acronyms
COVID-19: The coronavirus disease 2019.
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